CD4 Cell Counting Must Not Be Sidelined If We Are To Beat AIDS

CARES Initiative Hub sample collection in Uganda

New World Health Organization guidelines seek to find and protect those at greatest risk of advanced HIV disease.

Tom Chiller is Branch Chief of the Mycotic Division at the Centres for Disease and Control and Prevention.

Debra Boers is CEO of the Global Health Impact Group

Ben Cheng is a consultant who provides support on new technologies to aid treatment and diagnosis of HIV.

Counting cells is vital

Counting the number of CD4 cells in a patient’s blood is the only accurate way of monitoring how well their immune system is working and predicting the progression of HIV. To reinforce this, the World Health Organization (WHO) has issued new guidelines to advise that CD4 cell counting is an essential part of the initial diagnosis and management of advanced HIV disease.

“Up to 30 per cent of patients coming in have advanced HIV disease, which means their CD4 cell count is below 200,” explains Debi Boeras, CEO of The Global Health Impact Group, an organization that helps to integrate diagnostics and care. “These individuals are likely to be really sick and susceptible to cryptococcal meningitis, TB and other infections.”

CARES Initiative Patients"Up to 30% of patients have advanced HIV, which means their CD4 cell count is below 200."


Accurate diagnosis means effective treatment

Many patients with advanced HIV disease may look healthy, so accurate and early diagnosis is key to ensure they are put on an advanced package of care, that could prevent potentially fatal outcomes.

As Tom Chiller, Chief of the Mycotic Diseases branch at the Centres for Disease and Control and Prevention, explains, “If you put someone on antiretroviral therapy and you don’t know their CD4 count and the degree to which their immune system is compromised, they could develop IRIS - immune reconstitution inflammatory syndrome – from which they can die.” In response, ministries of health need to coordinate CD4 cell count testing on a national scale. “In South Africa they have about 64 CD4 labs and the samples come in and are processed very quickly. That type of system can work fantastically well, but only if you set it up and have the money to run it and maintain it,” continues Chiller.

CARES Initiative Men Walking


“The majority of countries still don’t have the infrastructure, transport or technology to effectively manage the blood samples.”


Improving infrastructure in rural communities

The majority of countries still don’t have the infrastructure, transport or technology to effectively manage the blood samples and communicate results back to patients and clinics. Despite advances in the quality and accuracy of diagnostic tests used for near-patient testing, it remains difficult to deliver equipment and supplies to keep the service running in hard to reach communities. Furthermore, with a rapid turnover of healthcare staff, maintaining consistency is an issue too.

But change is taking place. IT infrastructure that supports remote testing in rural areas is being developed. “One of the things we’ve been working on is connecting these near-patient technologies up to a central server, so the ministry knows where the devices are, if they’re working and if they’re being used properly,” says Ben Cheng, a specialist consultant who works with a range of partners to develop technologies to aid treatment and diagnosis of HIV.

CARES Initiative Mulago hospital"The longer it takes to link patients with treatment, the more likely they are to fall out of the system completely."


Integrating diagnostics and care

The longer it takes to link a patient with treatment, the more likely they are to drop out of the system completely. So, if we are to reduce mortality rates, then the final piece of the jigsaw is to connect patients identified as having advanced HIV disease with the correct package of care as quickly as possible.

“We have four key players: the patient, the clinician, the testing and the treatment,” continues Boeras. “In an ideal world we need to get them all into the same room. Bringing the testing together with the clinical support will help to engage people in the healthcare system.”

New WHO guidelines and technological advancements are all vital, but the health of those with HIV depends on specialists from different disciplines working together with a single focus on patient care.

For the role of CD4 in HIV analysis and patient management:

Download Brochure

*Photos courtesy of Dr. Charles Kiyaga


Please keep me informed about Beckman Coulter webinars, products, goods, and services, including products, goods, or services from our related companies.

By submitting this form I confirm that I have reviewed and agree with the Privacy Policy and Terms of Use. I also understand my privacy choices as they pertain to my personal data as provided in the Privacy Policy under “Your Privacy Choices”.

Uganda NHLS Lab Strengthening Pilot

Beckman Coulter Life Science and The CARES Initiative to fight HIV/AIDS has partnered with the Uganda National Health Laboratory Service within the Ministry of Health based in Kampala Uganda. The partnership was formed to support a laboratory strengthening Pilot. The Pilot will run 12 months.

The CARES Initiative Supports the UNAIDS 90-90-90 Target

More than 30 years after HIV first appeared, there are an estimated 37 million cases worldwide with nearly 70% of HIV+ patients living in Sb Saharan Africa followed by South East Asia, Latin America and Eastern Europe

HIV Diagnosis Up To Four Times Faster

Africa’s poorest and most vulnerable can benefit from simple HIV test which monitors disease progression, enabling governments to deliver comprehensive treatment programs. Improving diagnostics in rural communities Prof Debbie Glencross is Director and Principle Pathologist.

Global Initiative to Support the Fight Against HIV

The CARES initiative was launched and driven by a social and civic responsibility to support the fight against HIV. Public and private partnerships are being explored to identify areas for Beckman Coulter Life Sciences to contribute for the broader purpose.